SecBot SecBot
8-K ·Filed Mar 12, 2026

ATRA

Atara Biotherapeutics, Inc.
NEUTRAL
Impact 5/10
Horizonweeks Processed8mo ago SEC0001193125-26-103127
8-K context-dependent: Items 8.01
Actionable Insight • Neutral

Traders should monitor for the upcoming regulatory update in Q2 2026, which could significantly impact stock volatility depending on the FDA's feedback and path forward for tab-cel approval.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$6.90
T+0 close · Mar 12, 2026 · via day close
Latest settled
+43.77%
T+60 · $9.92
Vs SPY
+33.07%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 12 $6.90entry
  2. T+1 · 8mo ago −5.80%α −5.20% · $6.50
  3. T+5 · 8mo ago −25.80%α −24.82% · $5.12
  4. T+20 · 7mo ago −32.61%α −34.58% · $4.65
  5. T+60 · 5mo ago +43.77%α +33.07% · $9.92
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Atara Biotherapeutics announced that a Type A meeting with the FDA has been scheduled to discuss the Complete Response Letter for the Biologics License Application of tabelecleucel (tab-cel), developed with partner Pierre Fabre Pharmaceuticals. The company expects to provide a regulatory update in the second quarter of 2026.

Key Facts

  • Atara Biotherapeutics announced a scheduled Type A meeting with the FDA on March 12, 2026.
  • The meeting will address the Complete Response Letter (CRL) for the Biologics License Application (BLA) of tabelecleucel (tab-cel).
  • The BLA is held by partner Pierre Fabre Pharmaceuticals, with Atara's support.
  • The purpose is to discuss resubmission with additional efficacy data collected since the original submission.
  • A regulatory update is anticipated in the second quarter of 2026.

Financial Impact

No immediate financial impact disclosed; potential future revenue depends on successful BLA resubmission and approval.

revenuepipeline valueregulatory risk

Risk Factors

  • FDA may require additional clinical data or trials, delaying approval.
  • Resubmission may not result in approval, risking further regulatory setbacks.
  • Atara's market cap remains low ($45M), indicating high sensitivity to binary regulatory outcomes.

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-103127
Document: 0001193125-26-103127-index-headers.html0001193125-26-103127
Document: 0001193125-26-103127.txt0001193125-26-103127

Track record

11 reports on ATRA

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 10, 20266d ago S-3 Bearish 5/10 Entry $8.23 to $7.93 Now $6.40 +22.24% ▲ +3.65% +3.29% vs SPY
  2. Nov 10, 20266d ago 8-K Neutral 5/10 Entry $8.23 to $7.93 Now $6.40 −22.24% ▼ −3.65% −3.29% vs SPY
  3. Jun 26, 202620w ago 8-K Neutral 3/10 Entry $11.17 to $11.48 Now $6.40 −42.70% ▲ +2.78% +2.00% vs SPY
  4. Jun 15, 202622w ago 3 Neutral 2/10 Entry $9.62 to $9.67 Now $6.40 −33.47% ▲ +0.52% +1.77% vs SPY
  5. May 7, 202627w ago 8-K Neutral 4/10 Entry $9.93 to $8.34 Now $6.40 −35.55% ▼ −16.01% −16.84% vs SPY
  6. May 7, 202627w ago Insider Cluster Mixed 5/10 Entry $9.93 to $8.34 Now $6.40 −35.55% ▼ −16.01% −16.84% vs SPY
  7. Apr 24, 202629w ago DEFA14A Neutral 3/10 Entry $4.99 to $4.73 Now $6.40 +28.26% ▼ −5.21% −4.73% vs SPY
  8. Mar 17, 202634w ago S-3 Neutral 4/10 Entry $5.00 to $5.12 Now $6.40 +28.00% ▲ +2.40% +2.67% vs SPY
  9. Mar 12, 202635w ago 8-K Neutral 5/10 Viewing Entry $6.90 to $6.50 Now $6.40 −7.25% ▼ −5.80% −5.20% vs SPY
  10. Mar 3, 202636w ago 8-K Mixed 6/10 Entry $5.42 to $5.39 Now $6.40 +18.08% ▼ −0.55% −1.31% vs SPY
Showing 10 of 11

US Market Status

Market Closed · Opens in 6h 27m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 12, 2026